NCT04834778
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have at least one measurable lesion
Exclusions: Patients with symptomatic, untreated, or actively progressing CNS metastases – see trial for details; Patients with a history of leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04834778